Candriam SCA’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $62.3M | Buy |
2,590,328
+597,742
| +30% | +$15.6M | 0.28% | 76 |
|
|
2026
Q1 | $56M | Buy |
1,992,586
+19,837
| +1% | +$528K | 0.29% | 77 |
|
|
2025
Q4 | $49.1M | Sell |
1,972,749
-60,553
| -3% | -$1.53M | 0.25% | 92 |
|
|
2025
Q3 | $51.8M | Sell |
2,033,302
-207,653
| -9% | -$5.13M | 0.27% | 85 |
|
|
2025
Q2 | $54.3M | Buy |
2,240,955
+581,355
| +35% | +$13.6M | 0.31% | 77 |
|
|
2025
Q1 | $42.1M | Buy |
1,659,600
+1,237,099
| +293% | +$32.4M | 0.26% | 92 |
|
|
2024
Q4 | $11.2M | Buy |
422,501
+30,207
| +8% | +$819K | 0.06% | 246 |
|
|
2024
Q3 | $11.4M | Sell |
392,294
-383,303
| -49% | -$11.2M | 0.07% | 258 |
|
|
2024
Q2 | $21.7M | Sell |
775,597
-532,565
| -41% | -$14.7M | 0.13% | 154 |
|
|
2024
Q1 | $36.3M | Buy |
1,308,162
+426,371
| +48% | +$11.8M | 0.23% | 100 |
|
|
2023
Q4 | $25.4M | Buy |
881,791
+180,002
| +26% | +$5.44M | 0.18% | 127 |
|
|
2023
Q3 | $23.3M | Buy |
701,789
+28,675
| +4% | +$1.01M | 0.17% | 123 |
|
|
2023
Q2 | $24.7M | Sell |
673,114
-690,431
| -51% | -$26.9M | 0.18% | 136 |
|
|
2023
Q1 | $51.2M | Buy |
1,363,545
+28,007
| +2% | +$1.21M | 0.36% | 68 |
|
|
2022
Q4 | $68.4M | Sell |
1,335,538
-100,587
| -7% | -$4.82M | 0.46% | 45 |
|
|
2022
Q3 | $62.8M | Buy |
1,436,125
+644,675
| +81% | +$31.3M | 0.44% | 48 |
|
|
2022
Q2 | $41.5M | Buy |
791,450
+382,709
| +94% | +$19.5M | 0.34% | 73 |
|
|
2022
Q1 | $21.2M | Sell |
408,741
-34,336
| -8% | -$1.78M | 0.14% | 157 |
|
|
2021
Q4 | $26.2M | Buy |
443,077
+309,129
| +231% | +$15.3M | 0.17% | 144 |
|
|
2021
Q3 | $5.76M | Buy |
133,948
+9,123
| +7% | +$404K | 0.04% | 374 |
|
|
2021
Q2 | $4.89M | Sell |
124,825
-24,869
| -17% | -$967K | 0.03% | 411 |
|
|
2021
Q1 | $5.29M | Hold |
149,694
| – | – | 0.04% | 362 |
|
|
2020
Q4 | $5.5M | Sell |
149,694
-37,417
| -20% | -$1.37M | 0.04% | 371 |
|
|
2020
Q3 | $6.51M | Buy |
187,111
+11,127
| +6% | +$390K | 0.06% | 313 |
|
|
2020
Q2 | $5.46M | Sell |
175,984
-360,314
| -67% | -$12.2M | 0.06% | 317 |
|
|
2020
Q1 | $19.5M | Hold |
536,298
| – | – | 0.22% | 105 |
|
|
2019
Q4 | $19.9M | Buy |
536,298
+205,759
| +62% | +$7.33M | 0.21% | 105 |
|
|
2019
Q3 | $11.3M | Sell |
330,539
-35,532
| -10% | -$1.29M | 0.15% | 158 |
|
|
2019
Q2 | $15M | Sell |
366,071
-54,449
| -13% | -$2.16M | 0.19% | 127 |
|
|
2019
Q1 | $16.9M | Sell |
420,520
-58,047
| -12% | -$2.32M | 0.22% | 105 |
|
|
2018
Q4 | $19.8M | Sell |
478,567
-89,484
| -16% | -$3.71M | 0.3% | 66 |
|
|
2018
Q3 | $23.8M | Sell |
568,051
-47,403
| -8% | -$1.82M | 0.32% | 67 |
|
|
2018
Q2 | $21.2M | Sell |
615,454
-215,920
| -26% | -$7.38M | 0.34% | 67 |
|
|
2018
Q1 | $28M | Buy |
831,374
+62,340
| +8% | +$2.14M | 0.48% | 41 |
|
|
2017
Q4 | $26.4M | Buy |
769,034
+14,112
| +2% | +$481K | 0.46% | 49 |
|
|
2017
Q3 | $25.6M | Buy |
754,922
+522,702
| +225% | +$16.8M | 0.45% | 50 |
|
|
2017
Q2 | $7.4M | Sell |
232,220
-184,409
| -44% | -$5.82M | 0.14% | 180 |
|
|
2017
Q1 | $13.5M | Sell |
416,629
-316,858
| -43% | -$9.99M | 0.26% | 102 |
|
|
2016
Q4 | $22.6M | Sell |
733,487
-336,874
| -31% | -$10.3M | 0.52% | 47 |
|
|
2016
Q3 | $34.4M | Sell |
1,070,361
-346,258
| -24% | -$11.6M | 0.83% | 20 |
|
|
2016
Q2 | $47.3M | Buy |
1,416,619
+159,956
| +13% | +$5.11M | 1.23% | 11 |
|
|
2016
Q1 | $35.1M | Sell |
1,256,663
-184,726
| -13% | -$5.28M | 0.88% | 20 |
|
|
2015
Q4 | $44.1M | Sell |
1,441,389
-58,421
| -4% | -$1.84M | 1.18% | 14 |
|
|
2015
Q3 | $44.7M | Sell |
1,499,810
-86,368
| -5% | -$2.77M | 1.1% | 12 |
|
|
2015
Q2 | $50.5M | Buy |
1,586,178
+401,253
| +34% | +$13.1M | 1.05% | 11 |
|
|
2015
Q1 | $39.1M | Sell |
1,184,925
-542,035
| -31% | -$17.2M | 0.79% | 21 |
|
|
2014
Q4 | $51M | Buy |
+1,726,960
| New | +$49.5M | 1.07% | 9 |
|
Other funds holding PFE
Candriam SCA's PFE Position: Q2 2026 in Review
Candriam SCA increased its Pfizer (PFE) stake by 30% in Q2 2026, buying an estimated $15.6M and bringing the position to 2,590,328 shares worth $62.3M. The position accounts for 0.28% of the portfolio, ranked #76.
Candriam SCA first reported a position in PFE in Q4 2014 and has held it in 47 quarters since. The position peaked at $68.4M in Q4 2022. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Candriam SCA held 2,590,328 shares of Pfizer worth $62.3M as of Q2 2026.
- Candriam SCA bought 597,742 Pfizer shares in Q2 2026, an estimated $15.6M.
- Pfizer made up 0.28% of Candriam SCA's portfolio in Q2 2026, its #76 holding.
- Candriam SCA first reported a position in Pfizer in Q4 2014 and has held it in 47 quarters since.
- Candriam SCA's Pfizer position peaked at $68.4M in Q4 2022.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.